Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Cross-Species Immune Mapping
Are you currently facing high attrition rates for immune-modulating biologics due to poor human translational fidelity? Our NHP helps you secure IND approval and reduce clinical failure risk. We provide validated, human-relevant immunological data crucial for target validation and safety assessment
Secure IND Approval And Minimize Clinical Risks With Creative Biolabs'NHP Models!
Murine models cannot accurately replicate human immune response and cell heterogeneity, leading to catastrophic translational failures. NHPs provide the essential molecular and functional homology needed to generate predictive preclinical data for next-generation biologics and vaccines.
Overview of NHP Applications
What Are Our Research Areas?
Cross-Species Immune Mapping is a critical preclinical discipline centered on precisely characterizing the differences and, more importantly, the similarities between animal model and human immune systems at the cellular and molecular level. This research background is necessitated by the increasing complexity of immunotherapies, which target specific cells, receptors, or signaling pathways. Effective translational science requires moving beyond simple histological or bulk data to generate high-resolution atlases. This involves mapping cell-type compositions, gene expression profiles, and gene regulatory networks across various tissues (e.g., bone marrow, spleen, lymph nodes) in NHPs and humans to create a validated molecular blueprint. This approach ensures that a therapeutic's mechanism of action observed in the NHP model is truly orthologous to the mechanism expected in humans.
Why Choose Us?
NHPs, particularly cynomolgus and rhesus macaques, offer superior translational fidelity over rodent models, making them the gold standard for immune-based therapeutic evaluation:
- Genetic/Immunological Similarities: The cynomolgus monkey exhibits a strikingly higher degree of similarity in immune-associated gene expression patterns and cellular communications to humans than the mouse.
- Clinical Translational Relevance: NHPs possess anatomical and physiological similarities (e.g., organization of lymphoid tissues, drug metabolism) that directly translate to human clinical trial design and outcome prediction.
- Human-Relevant Cell Populations: NHPs possess key immune cell subsets and signaling pathway functionality (e.g., TLR responses) that are either absent or functionally divergent in mice, ensuring accurate assessment of drug safety and efficacy.
Fig.1 Detection of cross-reactive antibodies between humans and rhesus macaques.1
Key Applications
Creative Biolabs leverages NHP models and multi-omic profiling to answer the most challenging translational questions for our clients:
- Biologic Target Validation and Off-Target Binding: NHPs confirm the orthology of a therapeutic target across species. We map the receptor expression and cellular location across NHP and human immune tissues, ensuring the biologic engages the intended cell population and identifying potential safety risks from unintended off-target binding in relevant organs.
- Immunotoxicity and Cytokine Storm Prediction: Using NHP primary cells in vitro and in vivo, we model the systemic immune response to a therapeutic candidate. This allows us to quantify the induction of inflammatory signaling cascades that are predictive of human-relevant safety events like Cytokine Release Syndrome (CRS).
- Gene Regulatory Network (GRN) Assessment: Integrated cellular transcriptomic profiling in NHPs allows us to characterize cell-specific regulatory elements and reconstruct gene regulatory networks. This functional analysis helps evaluate whether a therapeutic or genetic payload modulates downstream signaling pathways in a manner consistent with human biology.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides end-to-end support for your NHP translational immunology program. Our services, highly relevant to Cross-Species Immune Mapping, include:
| Service Capability | Corresponding Application Area |
| Receptor Occupancy (Flow Cytometry) | Precision quantification of therapeutic binding on key immune cell subsets. |
| Integrated Bioinformatics Report | Interpreting and comparing multi-omic data from NHP and human samples. |
| Immunotoxicity & Cytokine Release Assays (CRAs) | Predicting human-relevant cytokine storm risk using NHP primary cells. |
| Proteomics & Metabolomics Pipelines | Complementing sequencing with deep protein and metabolite profiling for comprehensive immune response monitoring. |
Translational Impact
Leveraging NHP models for Cross-Species Immune Mapping is not just a scientific best practice—it is a regulatory and business imperative. By employing multi-omics, our clients gain the most predictive preclinical data available, significantly de-risking their pipeline. More reliable early proof of concept is established by confirming that a drug's mechanism of action (MOA) and immunotoxicity profile are consistent with human biology. This level of detail enables early detection of immune responses/toxicity long before they escalate into systemic problems, allowing for proactive dose adjustments and formulation optimization. Ultimately, this approach leads to a reduced risk of IND failure, as the data package presented to regulatory bodies is built upon the highest translational fidelity model available. For advanced therapies, NHP data proving that immunogenicity risks are manageable is critical for IND acceptance.
Frequently Asked Questions
Q: What types of NHP samples and tissues can you process for cross-species mapping?
A: We are equipped to handle a comprehensive range of NHP bio-specimens. This includes primary and secondary lymphoid organs such as spleen, lymph nodes, and bone marrow, as well as PBMCs, and other body fluids (e.g., CSF). We also offer Custom Collection Services to create longitudinal and donor-matched cohorts (age, sex, origin) specific to your study design.
Q: What precautions are taken to ensure sample stability and data quality during collection and processing?
A: Sample integrity is paramount. We adhere to rigorous SOPs utilizing our Cold-Chain Transportation and Full-Service Sample Management capabilities. All immune cell isolation (e.g., PBMCs) is performed rapidly by experienced technicians. For multi-omic analysis, cell viability is strictly monitored to ensure high-quality sequencing libraries and accurate capture of delicate RNA and chromatin accessibility signals.
Q: Can you apply these cross-species mapping techniques to non-immune tissues, such as the liver or CNS?
A: Absolutely. While our immune mapping is highly relevant for biologics and vaccines, the methodology of integrated regulomic and transcriptomic mapping is universally applicable. We routinely use this to dissect cell heterogeneity and disease pathology in other key organs, ensuring that your systemic therapeutic targets the correct cell population in tissues prone to off-target toxicity.
Q: What is the typical turnaround time for a full NHP atlas, and what is the final data format?
A: The turnaround time varies based on project scale (number of samples and desired depth). Generally, a comprehensive multi-omic atlas takes 8-12 weeks from sample receipt to final data delivery. You receive a fully annotated Integrated Bioinformatics Report.
Contact Us
Creative Biolabs is your dedicated partner in eliminating preclinical uncertainty. We provide the highest translational resolution using validated NHP models and cutting-edge multi-omic technologies. Our focus on markers for long-term immune protection ensures your program has the robust data required for clinical success. To discuss your specific project needs, including custom NHP cohort creation, bespoke biomarker identification, or multi-omic atlas generation, please reach out to our scientific development team.
Reference
- Staupe, Ryan P., et al. "Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells." Communications Biology 5.1 (2022): 1399. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s42003-022-04216-9